학술논문
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
Document Type
Article
Author
Pfister, C.; Gravis, G.; Flechon, A.; Chevreau, C.; Mahammedi, H.; Laguerre, B.; Guillot, A.; Joly, F.; Harter, V.; Soulie, M.; Allory, Y.; Culine, S.; PIGNOT, G.; FENDLER, J.P.; GUY, L.; VERHOEST, G.; MOTTET, N.; DOERFLER, A.; ABADIE LACOURTOISIE, S.; AZZOUZI, A.R.; MONGIAT, P.; GEOFFROIS, L.; ESCHWEGE, P.; DI FIORE, F.; ROUBAUD, G.; HOEPFFNER, J.L.; BARTHELEMY, P.; LANG, H.; VOOG, E.; MANDRON, E.; TOURANI, J.M.; SERRATE, C.; COLAU, A.; SALDANA, C.; DE LA TAILLE, A.; NGUYEN, T.; KLEINCLAUSS, F.; LORIOT, Y.; IRANI, J.; EYMARD, J.C.; LARRE, S.; HUILLARD, O.; ZERBIB, M.; ROLLAND, F.; RIGAUD, J.; HOUEDE, N.; DROUPY, S.; MALOUF, G.; ROUPRET, M.; VIEILLOT, S.; LETANG, N.; LHARIDON, T.; GASCHIGNARD, N.; HILGERS, W.; DAVIN, J.L.
Source
In: The Lancet Oncology . (The Lancet Oncology, February 2024, 25(2):255-264)
Subject
Language
English
ISSN
14745488
14702045
14702045